Verastem Stock Price, News & Analysis (NASDAQ:VSTM)

$3.31 +0.08 (+2.48 %)
(As of 02/19/2018 03:04 AM ET)
Previous Close$3.31
Today's Range$3.20 - $3.33
52-Week Range$1.11 - $5.71
Volume385,978 shs
Average Volume742,968 shs
Market Capitalization$142.32 million
P/E Ratio-2.02
Dividend YieldN/A
Beta2.2

About Verastem (NASDAQ:VSTM)

Verastem logoVerastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:VSTM
CUSIP92337C10
Phone+1-781-2924200

Debt

Debt-to-Equity Ratio0.06%
Current Ratio3.12%
Quick Ratio3.12%

Price-To-Earnings

Trailing P/E Ratio-2.01829268292683
Forward P/E Ratio-1.90
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.95 per share
Price / Book1.70

Profitability

Trailing EPS($1.64)
Net Income$-36,440,000.00
Net MarginsN/A
Return on Equity-110.32%
Return on Assets-85.98%

Miscellaneous

Employees32
Outstanding Shares48,370,000

Verastem (NASDAQ:VSTM) Frequently Asked Questions

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How were Verastem's earnings last quarter?

Verastem Inc (NASDAQ:VSTM) issued its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.29. View Verastem's Earnings History.

Where is Verastem's stock going? Where will Verastem's stock price be in 2018?

8 brokerages have issued twelve-month price objectives for Verastem's stock. Their predictions range from $1.50 to $17.00. On average, they expect Verastem's stock price to reach $10.36 in the next twelve months. View Analyst Ratings for Verastem.

What are Wall Street analysts saying about Verastem stock?

Here are some recent quotes from research analysts about Verastem stock:

  • 1. Cantor Fitzgerald analysts commented, "VSTM shares are up premarket on the news that the company submitted an NDA for approval of duvelisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), as well as for accelerated approval in relapsed or refractory follicular lymphoma (FL)." (2/7/2018)
  • 2. Cann analysts commented, "Verastem announced today that a poster highlighting the synergistic effects of Duvelisib in combination with immune checkpoint or co-stimulatory antibodies in preclinical models of B cell lymphoma was presented at ASCO-SITC Clinical Immuno- Oncology Symposium. The purpose of this study was to evaluate whether Duvelisib therapy could augment the efficacy of immune checkpoint inhibitors or co-stimulatory agents in the A20 mouse model of B cell lymphoma. Verastem reported that as a result of beneficial changes within the tumor microenvironment, it observed enhancement by Duvelisib of the anti-tumor efficacy of immune checkpoint or co-stimulatory antibodies in this preclinical B cell lymphoma model." (1/26/2018)
  • 3. According to Zacks Investment Research, "Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. " (11/8/2017)

Are investors shorting Verastem?

Verastem saw a increase in short interest in January. As of January 12th, there was short interest totalling 1,730,958 shares, an increase of 72.0% from the December 29th total of 1,006,283 shares. Based on an average trading volume of 897,858 shares, the days-to-cover ratio is presently 1.9 days. Currently, 4.0% of the company's stock are short sold.

Who are some of Verastem's key competitors?

Who are Verastem's key executives?

Verastem's management team includes the folowing people:

  • Robert Forrester, President, Chief Executive Officer (Age 52)
  • Julie B. Feder, Chief Financial Officer (Age 47)
  • Daniel W. Paterson, Chief Operating Officer (Age 53)
  • Joseph M. Lobacki, Executive Vice President and Chief Commercial Officer (Age 58)
  • Joseph Chiapponi, Vice President - Finance (Age 48)
  • Monica Kleinman, Vice President, General Counsel (Age 34)
  • Michael Ferraresso, Vice President - Commercial Operations
  • Lori A. Kunkel M.D., Clinical and Scientific Advisory Board (Age 59)
  • Hagop Youssoufian M.D., Head - Hematology and Oncology Development (Age 59)
  • Michael G. Kauffman M.D. Ph.D., Lead Independent Director (Age 53)

Who owns Verastem stock?

Verastem's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (4.65%), Renaissance Technologies LLC (3.50%), Artal Group S.A. (2.07%), AWM Investment Company Inc. (0.95%), Millennium Management LLC (0.74%) and Monashee Investment Management LLC (0.57%). Company insiders that own Verastem stock include Michael Kauffman and Timothy J Barberich. View Institutional Ownership Trends for Verastem.

Who sold Verastem stock? Who is selling Verastem stock?

Verastem's stock was sold by a variety of institutional investors in the last quarter, including Bogle Investment Management L P DE, Renaissance Technologies LLC, Deutsche Bank AG and Howland Capital Management LLC. View Insider Buying and Selling for Verastem.

Who bought Verastem stock? Who is buying Verastem stock?

Verastem's stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, AWM Investment Company Inc., Monashee Investment Management LLC, Artal Group S.A., Stonepine Capital Management LLC, Alambic Investment Management L.P., Millennium Management LLC and Two Sigma Investments LP. View Insider Buying and Selling for Verastem.

How do I buy Verastem stock?

Shares of Verastem can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Verastem's stock price today?

One share of Verastem stock can currently be purchased for approximately $3.31.

How big of a company is Verastem?

Verastem has a market capitalization of $142.32 million. The biopharmaceutical company earns $-36,440,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Verastem employs 32 workers across the globe.

How can I contact Verastem?

Verastem's mailing address is 117 Kendrick St Ste 500, NEEDHAM, MA 02494-2730, United States. The biopharmaceutical company can be reached via phone at +1-781-2924200 or via email at [email protected]


MarketBeat Community Rating for Verastem (VSTM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  260 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  414
MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Verastem (NASDAQ:VSTM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.882.832.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.36$10.64$7.75$4.75
Price Target Upside: 194.24% upside248.95% upside134.85% upside50.32% upside

Verastem (NASDAQ:VSTM) Consensus Price Target History

Price Target History for Verastem (NASDAQ:VSTM)

Verastem (NASDAQ:VSTM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/7/2018Cantor FitzgeraldReiterated RatingBuy$17.00MediumView Rating Details
1/26/2018CannReiterated RatingBuy$13.00LowView Rating Details
12/21/2017OppenheimerSet Price TargetBuy$13.00MediumView Rating Details
12/13/2017HC WainwrightSet Price TargetBuy$10.00MediumView Rating Details
12/11/2017Raymond James FinancialReiterated RatingBuyHighView Rating Details
12/1/2017Roth CapitalInitiated CoverageBuy$12.00HighView Rating Details
6/28/2017Jefferies GroupReiterated RatingHold$1.50HighView Rating Details
4/13/2017CIBCReiterated RatingOutperform -> Outperform$6.00HighView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Verastem (NASDAQ:VSTM) Earnings History and Estimates Chart

Earnings by Quarter for Verastem (NASDAQ:VSTM)

Verastem (NASDAQ VSTM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.32)($0.61)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.34)($0.36)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.35)($0.35)ViewN/AView Earnings Details
3/23/2017Q4 2016($0.27)($0.32)ViewN/AView Earnings Details
11/7/2016Q3($0.24)($0.21)ViewN/AView Earnings Details
8/8/2016Q2($0.29)($0.23)ViewN/AView Earnings Details
5/9/2016($0.30)($0.22)ViewN/AView Earnings Details
3/3/2016Q415($0.36)($0.32)ViewListenView Earnings Details
11/9/2015Q3 2015($0.43)($0.42)ViewN/AView Earnings Details
8/10/2015Q2($0.45)($0.42)ViewN/AView Earnings Details
5/11/2015Q1($0.41)($0.46)ViewN/AView Earnings Details
3/10/2015($0.54)($0.53)ViewN/AView Earnings Details
10/30/2014($0.51)($0.52)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.52)($0.51)ViewN/AView Earnings Details
5/8/2014($0.43)($0.51)ViewN/AView Earnings Details
3/6/2014Q4($0.47)($0.45)ViewListenView Earnings Details
11/12/2013Q3($0.44)($0.47)ViewN/AView Earnings Details
8/13/2013Q2 2013($0.41)($0.49)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.43)($0.44)ViewN/AView Earnings Details
3/27/2013Q4 2012($0.40)($0.39)ViewN/AView Earnings Details
11/13/2012Q3 2012($0.36)($0.51)ViewN/AView Earnings Details
8/13/2012Q2 2012($0.34)($0.34)ViewN/AView Earnings Details
5/14/2012Q1 2012($0.28)($0.47)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Verastem (NASDAQ:VSTM) Earnings Estimates

2018 EPS Consensus Estimate: ($2.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.47)($0.47)($0.47)
Q2 20181($0.47)($0.47)($0.47)
Q3 20181($0.52)($0.52)($0.52)
Q4 20181($0.54)($0.54)($0.54)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Verastem (NASDAQ:VSTM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Verastem (NASDAQ VSTM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.51%
Institutional Ownership Percentage: 29.10%
Insider Trades by Quarter for Verastem (NASDAQ:VSTM)
Institutional Ownership by Quarter for Verastem (NASDAQ:VSTM)

Verastem (NASDAQ VSTM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/5/2017Timothy J BarberichDirectorBuy60,538$3.95$239,125.10130,000View SEC Filing  
5/15/2017Timothy J BarberichDirectorBuy30,000$2.45$73,500.0069,462View SEC Filing  
6/29/2015Monica SinghGeneral CounselBuy1,000$6.95$6,950.00View SEC Filing  
6/29/2015Robert ForresterCEOBuy2,000$7.11$14,220.00View SEC Filing  
6/18/2015Dan PatersonCOOBuy1,000$8.05$8,050.00View SEC Filing  
6/17/2015Robert ForresterCEOBuy1,000$7.97$7,970.00View SEC Filing  
1/28/2015Christoph H WestphalChairmanBuy1,230,769$6.50$7,999,998.50View SEC Filing  
1/28/2015Timothy J BarberichDirectorBuy38,462$6.50$250,003.00View SEC Filing  
12/29/2014Joanna HorobinInsiderBuy750$8.60$6,450.00View SEC Filing  
12/29/2014S. Louise PhanstielDirectorBuy10,000$8.54$85,400.00View SEC Filing  
12/26/2014Stephen A SherwinDirectorBuy2,500$8.56$21,400.00View SEC Filing  
12/24/2014Paul A FriedmanDirectorBuy3,000$8.31$24,930.00View SEC Filing  
12/23/2014Henri A TermeerDirectorBuy19,100$8.09$154,519.00View SEC Filing  
12/23/2014Monica SinghGeneral CounselBuy1,000$8.09$8,090.00View SEC Filing  
12/19/2014Christoph H WestphalChairmanBuy1,500$8.50$12,750.00View SEC Filing  
12/19/2014Dan PatersonCOOBuy2,000$8.52$17,040.00View SEC Filing  
12/19/2014Robert ForresterCEOBuy1,000$8.66$8,660.00View SEC Filing  
11/11/2014Alison Frances LawtonDirectorBuy2,500$9.17$22,925.00View SEC Filing  
9/17/2014Michael KauffmanDirectorBuy3,000$9.10$27,300.00View SEC Filing  
5/30/2014Timothy J BarberichDirectorBuy1,000$9.90$9,900.00View SEC Filing  
5/20/2014Richard AldrichDirectorBuy1,000$8.37$8,370.00408,142View SEC Filing  
5/15/2014Dan PatersonInsiderBuy1,000$7.47$7,470.0058,143View SEC Filing  
5/14/2014Christoph WestphalChairmanBuy2,000$7.56$15,120.00700,264View SEC Filing  
5/13/2014Robert ForresterCEOBuy1,000$7.62$7,620.00239,320View SEC Filing  
11/18/2013Christoph WestphalDirectorBuy1,000$9.60$9,600.00696,872View SEC Filing  
11/11/2013Richard AldrichDirectorBuy1,000$10.93$10,930.00407,142View SEC Filing  
11/4/2013Richard AldrichDirectorBuy1,000$10.51$10,510.00View SEC Filing  
10/28/2013Richard AldrichDirectorBuy1,000$11.26$11,260.00View SEC Filing  
10/21/2013Richard AldrichDirectorBuy1,000$12.57$12,570.00View SEC Filing  
10/14/2013Richard AldrichDirectorBuy1,000$10.56$10,560.00407,142View SEC Filing  
10/7/2013Richard AldrichDirectorBuy1,000$11.53$11,530.00407,142View SEC Filing  
9/30/2013Richard AldrichDirectorBuy1,000$12.55$12,550.00407,142View SEC Filing  
9/23/2013Richard AldrichDirectorBuy1,000$13.17$13,170.00407,142View SEC Filing  
9/16/2013Richard AldrichDirectorBuy1,000$13.81$13,810.00407,142View SEC Filing  
9/9/2013Richard AldrichDirectorBuy1,000$14.04$14,040.00View SEC Filing  
9/3/2013Richard AldrichDirectorBuy1,000$14.07$14,070.00407,142View SEC Filing  
8/26/2013Richard AldrichDirectorBuy1,000$14.21$14,210.00407,142View SEC Filing  
8/19/2013Richard AldrichDirectorBuy1,000$13.45$13,450.00407,142View SEC Filing  
8/12/2013Richard AldrichDirectorBuy1,000$14.75$14,750.00407,142View SEC Filing  
8/5/2013Richard AldrichDirectorBuy1,000$15.25$15,250.00407,142View SEC Filing  
7/29/2013Richard AldrichDirectorBuy1,000$15.15$15,150.00View SEC Filing  
7/24/2013Richard AldrichDirectorBuy1,000$16.39$16,390.00View SEC Filing  
7/15/2013Richard AldrichDirectorBuy1,000$17.19$17,190.00View SEC Filing  
7/8/2013Richard AldrichDirectorBuy1,000$14.69$14,690.00View SEC Filing  
7/1/2013Richard AldrichDirectorBuy1,000$14.11$14,110.00View SEC Filing  
6/13/2013Robert ForresterCOOBuy1,000$11.39$11,390.00View SEC Filing  
6/12/2013Henri A TermeerDirectorBuy5,823$9.74$56,716.02View SEC Filing  
6/12/2013Lp Chp IIIMajor ShareholderBuy48,171$9.40$452,807.40View SEC Filing  
6/11/2013S. Louise PhanstielDirectorBuy12,000$9.30$111,600.00View SEC Filing  
6/7/2013Christoph H WestphalCEOBuy1,000$9.06$9,060.00View SEC Filing  
5/13/2013John K ClarkeDirectorBuy25,000$9.74$243,500.00View SEC Filing  
5/1/2013John K ClarkeDirectorBuy10,000$9.66$96,600.00View SEC Filing  
4/17/2013John K ClarkeDirectorBuy5,631$9.50$53,494.50View SEC Filing  
12/18/2012Lp Chp IIIMajor ShareholderBuy6,193$7.87$48,738.91View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Verastem (NASDAQ VSTM) News Headlines

Source:
DateHeadline
FY2020 EPS Estimates for Verastem Inc (VSTM) Raised by OppenheimerFY2020 EPS Estimates for Verastem Inc (VSTM) Raised by Oppenheimer
www.americanbankingnews.com - February 12 at 9:20 AM
Verastem Inc (VSTM) Receives Average Recommendation of "Buy" from AnalystsVerastem Inc (VSTM) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 10 at 5:38 AM
Verastem (VSTM) Receives "Buy" Rating from Cantor FitzgeraldVerastem (VSTM) Receives "Buy" Rating from Cantor Fitzgerald
www.americanbankingnews.com - February 7 at 11:30 AM
Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - February 7 at 9:41 AM
Verastem Submits New Drug Application to U.S. FDA for Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular LymphomaVerastem Submits New Drug Application to U.S. FDA for Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
finance.yahoo.com - February 7 at 9:41 AM
Verastem submits U.S. marketing application for lead candidate duvelisib; shares ahead 7% premarketVerastem submits U.S. marketing application for lead candidate duvelisib; shares ahead 7% premarket
seekingalpha.com - February 7 at 8:17 AM
Verastem Inc (VSTM) Short Interest UpdateVerastem Inc (VSTM) Short Interest Update
www.americanbankingnews.com - January 28 at 1:06 AM
Verastem (VSTM) Stock Rating Reaffirmed by CannVerastem (VSTM) Stock Rating Reaffirmed by Cann
www.americanbankingnews.com - January 26 at 8:08 PM
Verastem Presents Preclinical Data at ASCO-SITC Highlighting the Synergistic Effects of Duvelisib in Combination with Immune Checkpoint or Co-Stimulatory Antibodies in B Cell Lymphoma ModelVerastem Presents Preclinical Data at ASCO-SITC Highlighting the Synergistic Effects of Duvelisib in Combination with Immune Checkpoint or Co-Stimulatory Antibodies in B Cell Lymphoma Model
finance.yahoo.com - January 26 at 3:44 PM
Verastem Inc (VSTM) Receives Average Rating of "Buy" from BrokeragesVerastem Inc (VSTM) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 16 at 5:32 AM
Verastem Inc (VSTM) Expected to Announce Earnings of -$0.43 Per ShareVerastem Inc (VSTM) Expected to Announce Earnings of -$0.43 Per Share
www.americanbankingnews.com - January 8 at 11:04 PM
Reviewing Verastem (VSTM) and Its RivalsReviewing Verastem (VSTM) and Its Rivals
www.americanbankingnews.com - January 8 at 7:36 PM
Verastem Announces Increased Hercules Debt Facility - Business Wire (press release)Verastem Announces Increased Hercules Debt Facility - Business Wire (press release)
www.businesswire.com - January 4 at 4:24 PM
Verastem Announces Increased Hercules Debt FacilityVerastem Announces Increased Hercules Debt Facility
finance.yahoo.com - January 4 at 4:23 PM
Verastem Appoints Joseph Lobacki as Chief Commercial OfficerVerastem Appoints Joseph Lobacki as Chief Commercial Officer
finance.yahoo.com - January 4 at 10:31 AM
Verastem (VSTM) versus The Competition Critical AnalysisVerastem (VSTM) versus The Competition Critical Analysis
www.americanbankingnews.com - January 2 at 9:32 AM
Critical Survey: Verastem (VSTM) versus Its PeersCritical Survey: Verastem (VSTM) versus Its Peers
www.americanbankingnews.com - January 2 at 3:30 AM
Verastem (VSTM) & Its Peers Critical AnalysisVerastem (VSTM) & Its Peers Critical Analysis
www.americanbankingnews.com - December 23 at 3:36 PM
Verastem Inc (VSTM) Receives Consensus Rating of "Buy" from AnalystsVerastem Inc (VSTM) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - December 22 at 5:54 AM
Verastem (VSTM) Given a $13.00 Price Target by Oppenheimer AnalystsVerastem (VSTM) Given a $13.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - December 21 at 7:16 PM
Verastem (VSTM) & Its Rivals Financial ContrastVerastem (VSTM) & Its Rivals Financial Contrast
www.americanbankingnews.com - December 21 at 7:48 AM
Head-To-Head Survey: Verastem (VSTM) and Its RivalsHead-To-Head Survey: Verastem (VSTM) and Its Rivals
www.americanbankingnews.com - December 18 at 1:34 AM
Verastem (VSTM) Prices $25M Offering of Common StockVerastem (VSTM) Prices $25M Offering of Common Stock
www.streetinsider.com - December 17 at 10:30 AM
Verastem Announces Public Offering of Common StockVerastem Announces Public Offering of Common Stock
finance.yahoo.com - December 15 at 11:02 AM
Verastem Announces Pricing of Public Offering of Common StockVerastem Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - December 15 at 11:02 AM
3 Stocks to Watch on Friday: DDR Corp (DDR), Hess Corp. (HES) and Verastem Inc (VSTM)3 Stocks to Watch on Friday: DDR Corp (DDR), Hess Corp. (HES) and Verastem Inc (VSTM)
investorplace.com - December 15 at 8:36 AM
Verastem: Revisiting This Small Biotech Name After ASH - Seeking AlphaVerastem: Revisiting This Small Biotech Name After ASH - Seeking Alpha
seekingalpha.com - December 14 at 10:43 AM
Verastem Jumps on Leukemia Drug Study Results - Investopedia (blog)Verastem Jumps on Leukemia Drug Study Results - Investopedia (blog)
www.investopedia.com - December 13 at 10:56 AM
Verastem (VSTM) Reports Clinical Data from the Pivotal Phase 3 DUO - StreetInsider.comVerastem (VSTM) Reports Clinical Data from the Pivotal Phase 3 DUO - StreetInsider.com
www.streetinsider.com - December 13 at 10:56 AM
Verastem (VSTM) Given a $10.00 Price Target at HC WainwrightVerastem (VSTM) Given a $10.00 Price Target at HC Wainwright
www.americanbankingnews.com - December 13 at 9:18 AM
Today’s Research Reports on Trending Tickers: Array BioPharma and Verastem, Inc.Today’s Research Reports on Trending Tickers: Array BioPharma and Verastem, Inc.
finance.yahoo.com - December 12 at 11:01 AM
Cantor Fitzgerald Analysts Give Verastem (VSTM) a $17.00 Price TargetCantor Fitzgerald Analysts Give Verastem (VSTM) a $17.00 Price Target
www.americanbankingnews.com - December 11 at 10:10 PM
Verastems (VSTM) Buy Rating Reiterated at Raymond James FinancialVerastem's (VSTM) Buy Rating Reiterated at Raymond James Financial
www.americanbankingnews.com - December 11 at 5:08 PM
2 Biotech Stocks to Have On Your Radar Into the New Year2 Biotech Stocks to Have On Your Radar Into the New Year
finance.yahoo.com - December 11 at 4:31 PM
Verastems (VSTM) "Buy" Rating Reiterated at OppenheimerVerastem's (VSTM) "Buy" Rating Reiterated at Oppenheimer
www.americanbankingnews.com - December 11 at 1:26 PM
Verastem Announces Clinical Data from the Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaVerastem Announces Clinical Data from the Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
finance.yahoo.com - December 11 at 11:17 AM
Verastem Jumps on Leukemia Drug Study ResultsVerastem Jumps on Leukemia Drug Study Results
finance.yahoo.com - December 11 at 11:17 AM
Verastem Announces Clinical Data from the Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves ... - Business Wire (press release)Verastem Announces Clinical Data from the Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves ... - Business Wire (press release)
www.businesswire.com - December 10 at 4:32 PM
Timothy J. Barberich Purchases 60,538 Shares of Verastem, Inc. (VSTM) StockTimothy J. Barberich Purchases 60,538 Shares of Verastem, Inc. (VSTM) Stock
www.americanbankingnews.com - December 7 at 5:56 PM
Verastem to Present Results from Pivotal Phase 3 DUO Study in ... - Business Wire (press release)Verastem to Present Results from Pivotal Phase 3 DUO Study in ... - Business Wire (press release)
www.businesswire.com - December 7 at 4:37 PM
Verastem to Present Results from Pivotal Phase 3 DUO Study in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at a Research and Development Event at ASH 2017Verastem to Present Results from Pivotal Phase 3 DUO Study in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at a Research and Development Event at ASH 2017
finance.yahoo.com - December 5 at 12:18 PM
Verastem (VSTM) Cut to "Strong Sell" at ValuEngineVerastem (VSTM) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - December 1 at 11:52 PM
Verastem (VSTM) Earns Buy Rating from Analysts at Roth CapitalVerastem (VSTM) Earns Buy Rating from Analysts at Roth Capital
www.americanbankingnews.com - December 1 at 7:38 PM
30 Stocks Moving In Thursdays Mid-Day Session30 Stocks Moving In Thursday's Mid-Day Session
feeds.benzinga.com - November 30 at 1:44 PM
Pre-Open Movers 11/30: (SHLD) (SNPS) (ADMP) Higher; (BKS) (JNPR) (SMTC+) Lower (more...)Pre-Open Movers 11/30: (SHLD) (SNPS) (ADMP) Higher; (BKS) (JNPR) (SMTC+) Lower (more...)
www.streetinsider.com - November 30 at 11:14 AM
Verastem, Inc. (VSTM) Receives Average Rating of "Buy" from BrokeragesVerastem, Inc. (VSTM) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 27 at 5:56 AM
Options Traders Expect Huge Moves in Verastem (VSTM) Stock - NasdaqOptions Traders Expect Huge Moves in Verastem (VSTM) Stock - Nasdaq
www.nasdaq.com - November 20 at 12:09 PM
Options Traders Expect Huge Moves in Verastem (VSTM) StockOptions Traders Expect Huge Moves in Verastem (VSTM) Stock
finance.yahoo.com - November 20 at 12:09 PM
FY2017 EPS Estimates for Verastem, Inc. (VSTM) Lowered by Oppenheimer HoldingsFY2017 EPS Estimates for Verastem, Inc. (VSTM) Lowered by Oppenheimer Holdings
www.americanbankingnews.com - November 10 at 12:38 PM
Verastem to Present at Upcoming Investor ConferencesVerastem to Present at Upcoming Investor Conferences
finance.yahoo.com - November 9 at 9:41 AM

SEC Filings

Verastem (NASDAQ:VSTM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Verastem (NASDAQ:VSTM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Verastem (NASDAQ VSTM) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.